PD-L1 overexpression has also been described in cancer subtypes beyond those that have been so far considered for immune check point inhibitors [4, 10, 24–26], potentially opening this type of therapy to a larger and more diverse populations of cancer patients. The gene discussed is CD274; the disease is cancer.